Related references
Note: Only part of the references are listed.Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Shripad V. Bhagwat et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Adaptive informatics for multifactorial and high-content biological data
Bjorn L. Millard et al.
NATURE METHODS (2011)
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
Luis I. Toledo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
DataPflex: a MATLAB-based tool for the manipulation and visualization of multidimensional datasets
Bart S. Hendriks et al.
BIOINFORMATICS (2010)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
Ker Yu et al.
CANCER RESEARCH (2010)
Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer
Qingsong Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
Calvin K. Yip et al.
MOLECULAR CELL (2010)
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2009)
Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
Ker Yu et al.
CANCER RESEARCH (2009)
Optimal targeting of the mTORC1 kinase in human cancer
Heidi A. Lane et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110α
Eli R. Zunder et al.
CANCER CELL (2008)
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Beth Apsel et al.
NATURE CHEMICAL BIOLOGY (2008)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Functional interrogation of the kinome using nucleotide acyl phosphates
Matthew P. Patricelli et al.
BIOCHEMISTRY (2007)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways
RT Abraham
DNA REPAIR (2004)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E Jacinto et al.
NATURE CELL BIOLOGY (2004)
SWISS-MODEL: an automated protein homology-modeling server
T Schwede et al.
NUCLEIC ACIDS RESEARCH (2003)
Polarizable atomic multipole water model for molecular mechanics simulation
PY Ren et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2003)
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
K Hara et al.
CELL (2002)
Share Paper
